{
    "organizations": [],
    "uuid": "8a2722a0540275011a2254ce94fc044fa0a974b2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-moleculin-announces-patients-treat/brief-moleculin-announces-patients-treated-in-fda-approved-phase-i-ii-annamycin-clinical-trial-idUSASC09UVN",
    "ord_in_thread": 0,
    "title": "BRIEF-Moleculin Announces Patients Treated In FDA Approved Phase I/Ii Annamycin Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Moleculin Biotech Inc:\n* MOLECULIN ANNOUNCES PATIENTS TREATED IN FDA APPROVED PHASE I/II ANNAMYCIN CLINICAL TRIAL Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-04-04T20:36:00.000+03:00",
    "crawled": "2018-04-05T17:14:44.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "moleculin",
        "biotech",
        "inc",
        "moleculin",
        "announces",
        "patient",
        "treated",
        "fda",
        "approved",
        "phase",
        "annamycin",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}